Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 6/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14833257 | 1.00 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1MGLLSLC6A5MEN1 | |
| SCHEMBL14830396 | 0.91 | KMT2A (0.50) | L3MBTL3L3MBTL1MGLLMEN1KMT2A | |
| SCHEMBL14814550 | 0.91 | KMT2A (0.50) | L3MBTL3L3MBTL1MGLLMEN1KMT2A | |
| SCHEMBL14815072 | 0.90 | L3MBTL3 (0.55) | L3MBTL3L3MBTL1MGLLSLC6A5MEN1 | |
| SCHEMBL14815270 | 0.87 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1MGLLSLC6A5MEN1 | |
| SCHEMBL14833250 | 0.87 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1MGLLSLC6A5MEN1 | |
| SCHEMBL14833264 | 0.85 | MEN1 (0.53) | L3MBTL3L3MBTL1MGLLMEN1KMT2A | |
| SCHEMBL14815112 | 0.85 | MEN1 (0.53) | L3MBTL3L3MBTL1MGLLMEN1KMT2A | |
| SCHEMBL14815167 | 0.84 | KMT2A (0.50) | L3MBTL3L3MBTL1MGLLMEN1KMT2A | |
| SCHEMBL14833493 | 0.84 | KMT2A (0.50) | L3MBTL3L3MBTL1MGLLMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669255-B2 | Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers | ABBVIE INC. (US) | 2014-03-11 | — | — | US | claimed |
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
| US-8669255-B2 | Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers | ABBVIE INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | L3MBTL3 2198/4885L3MBTL1 2030/4885MGLL 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.